The Canadian consensus statement recommends achieving a serum testosterone level of less than 0.7nmol/l as there appears to be an associated clinical benefit9. Additional recommendations include regular monitoring of testosterone and PSA levels throughout the first year of ADT treatment, using...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.